Ailux Selected for Digital Oral and Poster Presentations at ECCO’26, Highlighting Potential for Novel IBD Treatment
February 17, 2026 SHANGHAI & SOMERVILLE, February 17, 2026 — Ailux, an AI-native biologics innovator and a subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced that it will present preclinical data from its TL1A/IL-23 bispecific antibody program at the European Crohn’s and Colitis Organisation (ECCO) Congress 2026, taking place February […]
Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
November 5, 2025 SHANGHAI, November 5, 2025 — Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company (“Lilly”) to accelerate the discovery and development of bispecific antibodies for the treatment of various […]
PEGS Boston 2025
July 18, 2025 Presentation by Patrick Doonan, Ph.D., Director of Alliance Management, Ailux
UCB Partners with Ailux on Biologics AI Platform
January 9, 2025 Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process These advancements have the potential to transform antibody discovery methods, broadening therapeutic applications and accelerating the development of innovative molecules BRUSSELS & CAMBRIDGE, MA, January 9th, 2025 — UCB, a global biopharmaceutical company, and XtalPi, a […]